Immunoglobulin E specific for Dolichovespula arenaria venom allergens (sIgE (Dol a))

IgE antibodies specific for Dolichovespula arenaria (aerial yellowjacket) venom epitopes are the primary mediators of Type I hypersensitivity reactions to this insect's sting (Golden, 2013, Journal of Allergy and Clinical Immunology). These antibodies are produced by B cells following sensitization to specific venom allergens, most notably Dol a 1 (phospholipase A1), Dol a 2 (hyaluronidase), and Dol a 5 (antigen 5) (WHO/IUIS Allergen Nomenclature Database, 2024). Upon re-exposure to the venom, these specific IgE (sIgE) molecules, which are bound to high-affinity FcεRI receptors on mast cells and basophils, trigger the cross-linking of receptors and subsequent release of inflammatory mediators like histamine and leukotrienes (StatPearls, 2023). This process can lead to clinical manifestations ranging from local swelling to life-threatening systemic anaphylaxis (Bilò et al., 2017, EAACI Guidelines). In therapeutic contexts, these antibodies are targeted indirectly by venom immunotherapy (VIT), which aims to shift the immune response toward IgG4 production and T-cell tolerance, or directly by monoclonal antibodies like omalizumab that sequester free IgE to prevent effector cell activation (Normansell et al., 2014, Cochrane Database).

Other names

Yellowjacket venom-specific IgEDol a sIgEAerial yellowjacket venom-specific IgEAnti-Dolichovespula arenaria IgE

Omalizumab binds to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the release of allergic mediators (National Center for Biotechnology Information, 2023).